Quantinno Capital Management LP Has $2.89 Million Stock Position in Fresenius Medical Care AG (NYSE:FMS)

Quantinno Capital Management LP grew its position in Fresenius Medical Care AG (NYSE:FMS - Free Report) by 16.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 127,726 shares of the company's stock after buying an additional 17,648 shares during the period. Quantinno Capital Management LP's holdings in Fresenius Medical Care were worth $2,892,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its holdings in shares of Fresenius Medical Care by 192.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock valued at $28,000 after buying an additional 806 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Fresenius Medical Care by 234.1% in the 4th quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company's stock valued at $71,000 after buying an additional 2,208 shares during the period. Jones Financial Companies Lllp grew its holdings in shares of Fresenius Medical Care by 80.5% in the 4th quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company's stock valued at $102,000 after buying an additional 2,012 shares during the period. Venturi Wealth Management LLC grew its holdings in shares of Fresenius Medical Care by 8.4% in the 4th quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company's stock valued at $129,000 after buying an additional 441 shares during the period. Finally, Assetmark Inc. lifted its position in Fresenius Medical Care by 196.3% in the 4th quarter. Assetmark Inc. now owns 7,210 shares of the company's stock valued at $163,000 after acquiring an additional 4,777 shares in the last quarter. Institutional investors and hedge funds own 8.37% of the company's stock.

Fresenius Medical Care Stock Performance

Shares of NYSE FMS opened at $29.11 on Tuesday. The stock has a 50 day moving average price of $25.08 and a 200 day moving average price of $23.80. Fresenius Medical Care AG has a 52 week low of $17.93 and a 52 week high of $29.57. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The stock has a market capitalization of $17.08 billion, a PE ratio of 24.06, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.43 by $0.01. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. The firm had revenue of $5.54 billion during the quarter, compared to analysts' expectations of $4.71 billion. Analysts predict that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Increases Dividend

The business also recently declared an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be given a dividend of $0.7871 per share. The ex-dividend date of this dividend is Friday, May 23rd. This is a boost from Fresenius Medical Care's previous annual dividend of $0.44. This represents a yield of 1.9%. Fresenius Medical Care's dividend payout ratio is 49.11%.

Wall Street Analyst Weigh In

Several research firms recently commented on FMS. StockNews.com began coverage on shares of Fresenius Medical Care in a research report on Tuesday. They issued a "strong-buy" rating on the stock. Morgan Stanley reaffirmed an "underweight" rating on shares of Fresenius Medical Care in a research report on Thursday. Finally, Truist Financial boosted their price objective on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the company a "hold" rating in a research report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Fresenius Medical Care presently has a consensus rating of "Hold" and an average price target of $27.80.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care AG (NYSE:FMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.